WSJ
Search documents
The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division
WSJ· 2026-02-12 02:00
Group 1 - The head of the agency's vaccine division, Vinay Prasad, has made a decision that overrides objections from career staffers [1]
WeRide Using AI to Cut Costs as It Grows Robotaxi Fleet
WSJ· 2026-02-12 01:56
Core Insights - The company has successfully reduced its data collection and training costs by 75% [1] - The company aims to at least double its fleet size within the current year [1]
Gold Falls on Prospects of Long Fed Pause
WSJ· 2026-02-11 23:41
Gold fell in the early Asian session amid prospects of a long Fed pause, which could reduce the appeal of the non-interest-bearing precious metal. ...
Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
WSJ· 2026-02-11 23:33
Core Viewpoint - The Swiss biopharmaceutical company's shares experienced a significant increase in after-hours trading following the FDA's approval of its Optune Pax product [1] Company Summary - The company is a Swiss biopharmaceutical firm that has recently received FDA approval for its product, Optune Pax [1] - The approval has positively impacted the company's stock performance, leading to a surge in share prices during after-hours trading [1] Industry Summary - The FDA's approval of new biopharmaceutical products is a critical factor influencing stock prices and investor sentiment within the biopharmaceutical industry [1] - The successful launch of innovative products like Optune Pax can enhance a company's market position and drive future growth in the biopharmaceutical sector [1]
Fed's Miran Says Rates Cuts Still Possible Following Strong Jobs Report
WSJ· 2026-02-11 22:51
Core Viewpoint - The Federal Reserve governor believes there is a valid argument for cutting interest rates following a better-than-expected jobs report for January [1] Group 1 - The January jobs report exceeded expectations, which may influence monetary policy decisions [1]
Pilgrim's Pride Fourth-Quarter Profit Slides, Hurt by Challenging Commodity Trends
WSJ· 2026-02-11 22:28
Group 1 - The company reported a profit of $88 million despite facing pressure from weaker commodity trends [1]
CoreCivic Says ICE Crackdown is Boosting Sales
WSJ· 2026-02-11 21:53
Group 1 - Management revenue from ICE, the largest government partner of the company, more than doubled year over year [1]
New AI Worries End Dow Industrials' Three-Session Winning Streak
WSJ· 2026-02-11 21:45
Core Viewpoint - Financial stocks have experienced a decline as Wall Street's mixed sentiments regarding artificial intelligence have hindered market momentum [1] Group 1: Financial Stocks Performance - Financial stocks are falling, indicating a lack of confidence in the sector amidst fluctuating market sentiments [1] - The decline in financial stocks reflects broader concerns about the impact of artificial intelligence on the industry [1] Group 2: Market Sentiment - Wall Street is described as having a "schizophrenic personality," suggesting inconsistent reactions to news and developments in artificial intelligence [1] - The mixed feelings about artificial intelligence are causing uncertainty, which is stalling momentum in the financial markets [1]
Cisco Sales Rise as AI Hyperscalers Drive Demand
WSJ· 2026-02-11 21:31
The company posted a second-quarter profit of $3.18 billion, up from $2.43 billion a year earlier. ...
AppLovin Profit Rises as Sales Jump
WSJ· 2026-02-11 21:20
Core Insights - The advertising company reported a significant revenue increase of 66%, reaching $1.66 billion compared to $599.2 million in the previous year [1] Financial Performance - Revenue surged to $1.66 billion, marking a 66% increase year-over-year [1] - Previous year's revenue was reported at $599.2 million [1]